Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charit\u00e9 - Universit\u00e4tsmedizin Berlin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM\u2013002 (S-oxprenolol) for Treating Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","amount":"$134.7 million","upfrontCash":"$2.7 million","newsHeadline":"Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Successfully Closed of \u00a32.5m Extended Seed B Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Successfully Closes Second Tranche Of \u00a310m Seed Financing To Progress Pipeline For Treatment Of Cancer Cachexia And Other Muscle Wasting Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of \u00a35 Million to Advance Clinical Development of Lead Programme for Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Announces FDA Approval of its Investigational New Drug Application for Phase 2b\/3 IMPACT Clinical Trials of S-Pindolol Benzoate to Treat Cancer Cachexia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Actimed Therapeutics

    Menu

    Actimed Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Actimed Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Announces FDA Approval of its Investigational New Drug Application for Phase 2b/3 IMPACT Clinical Trials of S-Pindolol Benzoate to Treat Cancer Cachexi...

              Details:

              ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2/3 clinical data in cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung cancer.

              Lead Product(s): S-pindolol Benzoate

              Therapeutic Area: Oncology Product Name: ACM-001.1

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of £5 Million to Advance Clinical Development of Lead Programme for Cancer Cachexia

              Details:

              The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.

              Lead Product(s): S-pindolol Benzoate

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mankind Pharma

              Deal Size: $6.3 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Successfully Closes Second Tranche Of £10m Seed Financing To Progress Pipeline For Treatment Of Cancer Cachexia And Other Muscle Wasting Disorders

              Details:

              ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.

              Lead Product(s): Pindolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mankind Pharma

              Deal Size: $12.1 million Upfront Cash: Undisclosed

              Deal Type: Financing January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents

              Details:

              S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.

              Lead Product(s): Pindolol

              Therapeutic Area: Musculoskeletal Product Name: ACM-001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round

              Details:

              The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.

              Lead Product(s): Pindolol

              Therapeutic Area: Oncology Product Name: ACM-001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $3.4 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing June 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

              Details:

              Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).

              Lead Product(s): Oxprenolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Faraday Pharmaceuticals

              Deal Size: $134.7 million Upfront Cash: $2.7 million

              Deal Type: Licensing Agreement April 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia

              Details:

              ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.

              Lead Product(s): Oxprenolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité - Universitätsmedizin Berlin

              Details:

              Actimed Therapeutics has licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin (Charité). This gives Actimed global rights in this indication.

              Lead Product(s): Oxprenolol

              Therapeutic Area: Neurology Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Charité Universitätsmedizin

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY